ARCHIVES

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

This article is from The Cancer Letter archive.

Vol. 01 No. 30 | July 25, 1975

Download PDF Visit The Full Archive

Related Articles

IOM Says “Immediate Steps” Needed To Avert “Crisis” In Cancer Centers Program Funding

April 28, 1989

Senate Vote On Override Of NIH Reauthorization Veto Delayed Until After US-USSR Summit Meeting

November 22, 1985

Two-Week Break Balances RT Palliation, Side Effects

February 26, 2010

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003

In Brief: Peter Pisters named CEO of University Health Network in Toronto

August 8, 2014

In Brief: Healy Nominated to Head NIH; Hammond, D’Angio To Step Down as Group Chairman

January 18, 1991